The prevalence of abdominal obesity in Slovakia. The IDEA Slovakia study.

Česká verzia

Authors: A. Dukát ¹; J. Lietava ¹; B. Krahulec ¹; M. Čaprnda ¹; I. Vacula ¹; J. Sirotiaková ²; V. Kosmálová ¹; P. Minárik Za Riešiteľov Štúdie Idea Slovakia ²
Authors place of work: II. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Andrej Dukát, CSc., FESC ¹; II. interná klinika Univerzity Konštantína Filozofa a FNsP Nitra, Slovenská republika, prednostka doc. MUDr. Jana Sirotiaková, Ph. D. ²
Published in the journal: Vnitř Lék 2007; 53(4): 326-330
Category: Original Contributions

Summary

Abdominal obesity represents an independent risk factor for subsequent severe cardiovascular events. It is one of the important diagnostic criteria for Metabolic Syndrome whose predictive value for severe cardiovascular events is similar to that of elevated LDL-cholesterol levels. The prevalence of abdominal obesity in the context of Metabolic Syndrome still has not been systematically monitored in Slovakia. The IDEA program evaluated a sample of 4183 patients in 103 centres in Slovakia. It has shown that only one in three adult inhabitants of Slovakia has a normal body weight. Almost every second inhabitant of Slovakia has intraabdominal obesity (by ATP III criteria). Obesity was recorded in every third woman (34.7 %) and in every fourth man (27.0 %). The prevalence of the principal risk factors (hypertension, hyperlipoproteinemia and diabetes mellitus) grew in proportion to the increase in waist circumference.

Key words:
obesity – epidemiology – Metabolic Syndrome – cardiovascular risk

Zdroje

1. Svačina Š, Owen K. Obezita, diabetes 2. typu a jejich kvantitativní vztahy. Vnitř Lék 2002; 48: 500-506.

2. Kahn HR, Buse J, Ferrani E. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 289-304.

3. The International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005, 1-7.Info@idf.org.

4. Hu G, Qiao Q, Tuomilehto J et al. Prevalence of the metabolic syndrome and its relation to all cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.

5. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002; 288: 2709-2716.

6. National Institutes of Health. The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary, Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute 2001. NIH Publ No 01-3670.

7. Albert MA, Glynn RJ, Buring J et al. Impact of Traditional and Novel Risk Factors on the Relationship Between Socioeconomic Status and Incident Cardiovascular Events. Circulation 2006; 114: 2619-2826.

8. Pickering TG. Cardiovascular pathways: socioeconomic status and stress effects on hypertension and cardiovascular function. Ann NY Acad Sci 1999; 896: 267-277.

9. Lynch JW, Kaplan GA, Cohen RD et al. Do cardiovascular risk factors explain the relation between socioeconomic status, risk for all-cause mortality, cardiovascular mortality and acute myocardial infarction? Am J Epidemiol 1966; 144: 934-942.

10. Dukát A, Lietava J, Krahulec B et al. IDEA - prvé výsledky o prevalencii abdominálnej obezity na Slovensku. Via Pract 2006; 3: 554-557.

11. Čaprnda M, Lietava J, Fodor JG. Metabolic syndrome and its association with cardiovascular diseases in Slovakia. Cor Vasa 2004; 46: 12-13.

12. Ben Yahia R, Lichnovská R, Janušová L et al. Zdravé osoby versus pacienti s diagnózou diabetes mellitus 2.typu - vybrané parametry v séru a v subkutánní abdominální tukové tkáni. Vnitř Lék 2007; 53: 9-17.

13. Haluzík M. Metabolický syndrom a tuková tkáň: opravdu za všechno mohou adipocyty? Editorial. Vnitř Lék 2007; 53: 5-6.

14. Ford ES, Giles WH, Detry WH. Prevalence of the Metabolic syndrome among US Adults. JAMA 2002; 287: 356-359.

15. Greenland P. Critical questions about the metabolic syndrome. Circulation 2005; 112: 3675-3676.

16. Fodor JG, Frohlich JJ, Genest JJ jr et al. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. Can Med Assn J 2000; 162: 1441-1447.

17. Joint British Societies Guidelines on Prevention of Cardiovascular Diseases in Clinical Practice. Heart 2005; 91(Suppl 5): 1-52.